Vitamin K1 to Slow Progression of Vascular Calcification in HD Patients

NCT ID: NCT01742273

Last Updated: 2020-10-08

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 63 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-10-31
• Study Completion Date: 2020-07-17

Brief Summary

Patients on hemodialysis (HD) exhibit an immensely increased cardiovascular mortality associated with extensive vascular calcification (VC). In the past years the development of VC was discovered to be actively regulated and as being influenced by inhibitors of calcification (e.g. matrix-Gla-protein, fetuin-A). MGP is produced by vascular smooth muscle cells and needs post-translational modification by vitamin K dependent gamma-carboxylation to be fully active. Based on the demonstration of increased PIVKA-II levels, about 97% of all HD patients exhibit insufficient carboxylation activity. We therefore aim in this randomized, controlled study to retard the progress of coronary and aortal calcification as assessed by thoracic multislice-CT by the thrice weekly administration of 5 mg vitamin K1 (phylloquinone) to about 100 HD patients over a period of 18 months.

Detailed Description

Patients on hemodialysis (HD) exhibit an immensely increased cardiovascular mortality associated with extensive vascular calcification (VC). This forms - at least partially - the reason for the excessively increased cardiovascular mortality in this population.

In the past years the development of VC was discovered to be actively regulated and as being influenced by inhibitors of calcification (e.g. matrix-Gla-protein, fetuin-A). Matrix Gla protein (MGP) is a powerful vascular wall-based inhibitor of VC. MGP is produced by vascular smooth muscle cells and needs post-translational modification by vitamin K dependent gamma-carboxylation to be fully active. The role of MGP was discovered in knock-out mice, which died from rupture of a massively calcified aorta. Functional vitamin K deficiency induced by administration of warfarin leads to the development of VC, which in turn can be inhibited by subsequent administration of vitamin K1. Warfarin inhibits the vitamin K mediated gamma-carboxylation, which leads to the production of noncarboxylated and inactive MGP (ucMGP).

Warfarin is widely used due to its inhibitory capacity on the activation of coagulation factors. Now it has been discovered that the use of vitamin K inhibitors influences vascular health: long-term use of warfarin is associated with an increased prevalence and extent of VC in the normal population and HD patients. Warfarin is also a crucial risk factor for the development of calciphylaxis, a life-threatening complication in HD patients characterised by calcified cutaneous vessels. In turn, administration of vitamin K1 was accompanied by reduced intima-media-thickness (IMT) and increased elasticity of vessels in postmenopausal women.

Based on the demonstration of increased PIVKA-II levels, about 97% of all HD patients exhibit insufficient carboxylation activity. Together with the increased VC they represent an ideal population for interventional trials in the vitamin K system. Recently we were able to demonstrate that supplementation of vitamin K1 in such patients is well tolerated, shows only very few side effects and induces a dose dependent decrease of the inactive form Dephosphorylated noncarboxylated matrix Gla protein (dpucMGP) in serum over a six weeks period. In this trial we also observed that all dialysis patients included had insufficient vitamin K serum levels, indicating no substantial influence of food intake on vitamin K deficiency. In addition, this demonstrates that all patients have insufficient vitamin K levels to facilitate adequate MGP carboxylation.

Conditions

Cardiovascular Diseases

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

standard treatment (usual care)

standard treatment (usual care)

Group Type: NO_INTERVENTION

No interventions assigned to this group

Vitamin K1

Vitamin K1 (phylloquinone), thrice weekly p.o. (5mg)

Group Type: EXPERIMENTAL

Vitamin K1

Intervention Type: DRUG

Vitamin K1 to slow vascular calcification

Interventions

Vitamin K1

Vitamin K1 to slow vascular calcification

Intervention Type: DRUG

Other Intervention Names

KA-Vit Tropfen (phylloquinone)

Eligibility Criteria

Inclusion Criteria

• Male or Female minimum 18 years of age
• Not less than 6 months on hemodialysis
• Cardiovascular calcification percent (coronary artery volume score > 100)
• Written consent to take part in the study
• Life expectancy not less than 18 months

Exclusion Criteria

• Known hypersensitivity against Vitamin K1
• History of thrombosis
• intake of Vitamin K
• tumor disease
• pulse >100/min (resting heart rate)
• Intake of vitamin K antagonists (e.g. Marcumar) at baseline or in the 3 months prior to baseline
• Inflammatory bowel disease
• Short-bowel syndrome
• Significant liver dysfunction
• more than one stent in one coronary artery plus one or more stents in an additional artery
• Hemoglobin < 70 g/L
• Women who are pregnant or breastfeeding
• Women without sufficient contraception
• Alcohol or drug abuse
• Mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study
• Subject unlikely to comply with protocol, e.g. uncooperative attitude, inability to return for follow-up-visits and unlikelihood of completing the study
• Participation in a parallel clinical trial or participation in another clinical trial within the previous 3 months
• Subjects who are in any state of dependency to the sponsor or the investigators
• Employees of the sponsor or the investigators
• Subjects who have been committed to an institution by legal or regulatory order

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

RWTH Aachen University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jürgen Floege, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

University Hospital of RWTH Aachen -Department of Medicine II, Nephrology and Clinical Immunology

Locations

Université catholique de Louvain - Department of Nephrology

Brussels, , Belgium

UZ Leuven, Dept. of Nephrology

Leuven, , Belgium

KfH Curatorship for Dialysis and Renal transplantation e.V.

Aachen, , Germany

University Hospital of RWTH Aachen, Department of Medicine II

Aachen, , Germany

Clinical Center of Coburg - Department of Medical Clinic III, Nephrology

Coburg, , Germany

MVZ DaVita Düsseldorf

Düsseldorf, , Germany

KfH Curatorchip for Dialysis and Renal Transplantation e.V.

Düsseldorf, , Germany

University Hospital Düsseldorf - Department of Nephrology

Düsseldorf, , Germany

MVZ Diaverum Erkelenz/ Heinsberg

Erkelenz, , Germany

University hospital of Erlangen - Department of Medicine 4, Nephrology and Hypertension

Erlangen, , Germany

Internistische Facharztpraxis, Abteilung Kardiologie - Nephrologie, Dialyse Geilenkirchen

Geilenkirchen, , Germany

KfH Curatorchip for Dialysis and Renal Transplantation e.V.

Stolberg, , Germany

University Hospital at Huddings, Karolinska Institute Stockholm - Department of Renal Medicine K56

Stockholm, , Sweden

Countries

Belgium; Germany; Sweden

Other Identifiers

2010-021264-14

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

VitaVasK

Identifier Type: -

Identifier Source: org_study_id